PDCD1 and breast cancer: Recently, anti-PD1 antibody (nivolumab) has been found to be ineffective against metastatic renal cell carcinoma, advanced squamous cell carcinoma, non-small-cell lung cancer, melanoma, or luminal-like breast cancer [48, 49].